Fundraising Fox
Evozyne
Chicago, US · Founded 2020 · 55 employees on LinkedIn · 8 known investors
Find your way into Evozyne
Sign up to see every warm intro you have to Evozyne
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Evozyne team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases. The company develops novel biologics and a pipeline of engineered proteins aimed at clinical use.
Founders & leadership
Board
Investors · 8
How we know: Paragon Biosciences LLC's portfolio page · the company's own site · pharmaceutical-technology.com · Not right? Tell us
How we know: In-Q-Tel's portfolio page · Not right? Tell us
How we know: pharmaceutical-technology.com · nvidia.com · Not right? Tell us
How we know: OrbiMed's portfolio page · a partner's Signal profile · funding news · pharmaceutical-technology.com · the VCSheet dataset · Not right? Tell us
How we know: Valor Equity Partners's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$144.4M disclosed across 3 rounds · 2020–2023
▶$81MraisedSep 2023 · 29 investors · BiotechnologyRule 506(b)
- Antonio GraciasDirector
- Jeffrey S. AroninExecutive Officer, Director
- Aris TheologisExecutive Officer
- Darien ParhadExecutive Officer
- Jude M. SullivanExecutive Officer
- Aleina LeeExecutive Officer
- Rama RanganathanExecutive Officer, Director
- Patrick J. MorrisExecutive Officer, Director
- Mike GamsonExecutive Officer, Director
- Matthew RizzoDirector
- Arjun RallapalliExecutive Officer
- Offering amount
- $100M
- Amount sold
- $81M
- Sales commissions
- $2M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$54.2MraisedApr 2021 · 12 investors · BiotechnologyRule 506(b)
- Aris TheologisExecutive Officer, Director
- Rama RanganathanExecutive Officer, Director
- Darien ParhadExecutive Officer
- Patrick J. MorrisExecutive Officer, Director
- Jeffrey S. AroninDirector
- Antonio GraciasDirector
- Offering amount
- $59.2M
- Amount sold
- $54.2M
- Sales commissions
- $1.6M
- Placement agents
- Paragon Health Capital
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$9.2MraisedMay 2020 · 2 investors · BiotechnologyRule 506(b)
- Aris TheologisExecutive Officer, Director
- Rama RanganathanExecutive Officer, Director
- Darien ParhadExecutive Officer
- Jeffrey S. AroninExecutive Officer, Director
- Antonio GraciasDirector
- Patrick J MorrisExecutive Officer, Director
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- First sale
- Apr 2020
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Evozyne do?
- Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases. The company develops novel biologics and a pipeline of engineered proteins aimed at clinical use.
- Who are Evozyne's investors?
- Evozyne's investors include Paragon Biosciences LLC, In-Q-Tel, NVIDIA, OrbiMed, Valor Equity Partners, Fidelity Investments, NVentures.
- How much funding has Evozyne raised?
- Evozyne has disclosed $144.4M raised across 3 rounds.
- Where is Evozyne headquartered?
- Evozyne is headquartered in Chicago, US.